Clinical Trials Browser

Phase EARLY_PHASE1 × Immunotherapy × 90 days × Clear all

NCT03387553 2026-02-09

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Phase EARLY_PHASE1 Active not recruiting

Breast Neoplasms, Breast Neoplasms, Male